Search the Newsreel

FY2030 EPS Estimates for Palisade Bio Reduced by Analyst

HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed?

Kyntra Bio, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KYNB) 2026-08-16

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns

Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly …

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

S&CO Inc. Buys Shares of 76,614 Bio-Techne Corp $TECH

S&CO Inc. has acquired a new stake of 76,614 shares in Bio-Techne Corp (NASDAQ:TECH), valued at approximately $5.41 million. Other institutional investors have also adjusted their positions in the biotechnology company, with institutional investors and hedge funds collectively owning 98.95% of its stock. Bio-Techne …

(PLSE) Risk Channels and Responsive Allocation

This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. …

ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal

BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated …

Focus Partners Advisor Solutions LLC Buys New Position in Biogen Inc. $BIIB

Focus Partners Advisor Solutions LLC has acquired a new position in Biogen Inc. by purchasing 7,689 shares valued at approximately $1,661,000 during the second quarter. Several other institutional investors also adjusted their holdings in Biogen, which continues to hold a "Moderate Buy" consensus rating …

Quantinno Capital Management LP Purchases 36,144 Shares of Castle Biosciences, Inc. $CSTL

Quantinno Capital Management LP significantly increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 387.3% in the first quarter, acquiring an additional 36,144 shares. This brings their total holdings to 45,476 shares, valued at approximately $1.12 million. While institutional investors own a large portion …

BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of "Hold" by Brokerages

BioLife Solutions (NASDAQ:BLFS) has received an average "Hold" recommendation from brokerages, with the majority of analysts issuing a hold rating. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite positive institutional investor activity, insiders have sold a …

Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts

Emergent Biosolutions Inc. (NYSE:EBS) has received an average "Hold" rating from analysts, with an average 12-month price target of $10.00. The company recently reported better-than-expected quarterly EPS of $0.60 and revenue of $234.3 million, though it posted a negative net margin and analysts anticipate …

Harmony Biosciences Holdings (HRMY), Why Is It Getting Fresh Attention?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Nuvation Bio (NUVB) Is Down 5.8% After Wider Q2 Loss Despite Surging Revenue And IBTROZI Focus

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average "Moderate Buy" rating from seven brokerages, with five analysts issuing buy recommendations. The company has an average 12-month price target of $15.33. Recent institutional activity shows increased holdings by major firms like BlackRock Inc., Adage Capital …

Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued?

Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …

Cytek (CTKB) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Full Conference Call Transcript Operator: Hello, and thank you for standing …

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of …

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …

How Ginkgo Bioworks Holdings Inc. Class A (DNA) Affects Rotational Strategy Timing

The article analyzes Ginkgo Bioworks Holdings Inc. Class A (DNA) stock performance and its impact on rotational strategy timing. It highlights a weak sentiment signaling long-term weakness resumption and identifies a significant short setup with a 100.0:1 risk-reward ratio. The report provides three AI-generated …

Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal

AbCellera Biologics (ABCL) saw its stock rise by 64.2% following positive Phase 2 results for its menopause drug ABCL635, a US$200 million equity raise, and a new collaboration with Vertex Pharmaceuticals. These developments strengthen its clinical pipeline and funding base, with the Vertex deal …

The Bull Case For BioNTech (BNTX) Could Change Following Cut 2026 Guidance And Deeper Losses

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

Top Generate Biomedicines (GENB) Competitors 2026

Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?

What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera (ABCL) saw its stock price jump by 64% last week, becoming the top-performing mid-cap stock in the US market, following strong phase 2 clinical trial results for its drug candidate ABCL635 for hot flashes in menopausal women. The drug successfully reduced hot flash …

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next